skip to main content

ES
Last Updated: 12/27/2024

Guselkumab

Drug Name(s): Tremfya

Class: Biologics

Type: IL-Inhibitor, IL-23

Used in the treatment of psoriatic arthritis (PsA) in adults and in children aged 6 and older who weigh at least 40 kg.

Dosage

Form(s): prefilled syringe 

100 mg administered by subcutaneous injection at week 0, week 4 and every 8 weeks thereafter.

Special Instructions

Keep refrigerated but do not freeze. Do not shake the filled syringe. Before injection, allow guselkumab to reach room temperature without removing the needle cap. Can be used alone or in combination with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate.

Potential Side Effects

Infection (fever, chills, wounds that don't heal); headache, pain, injection site redness or swelling, joint pain, and stomach problems (diarrhea, abdominal pain). It’s possible to have a severe allergic reaction after first dose (skin rash, nausea, vomiting, difficulty breathing).

Be Aware

This and all biologics suppress the immune system and may increase your risk of infections. Tell your doctor if you have an active infection. Do not start treatment if you have a serious or recurrent infection (such as pneumonia). You should be tested for tuberculosis before starting this medication. Do not get a live vaccine when taking biologics.

The Arthritis Foundation’s Drug Guide is meant for education — not self-medicating. The Arthritis Foundation does not endorse any products mentioned in this guide. While we endeavor to keep the information up to date, we make no representations or warranties about the completeness of the information provided.